AmerisourceBergen Launches Cell and Gene Therapy Integration Hub

AmerisourceBergen announced the launch of its platform agnostic Cell and Gene Therapy (CGT) Integration Hub, to offer CGT developers support including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution and patient support services.

Using AmerisourceBergen’s customer relationship management system – the goal is to streamline the path-to-care process, in part, by providing physicians and patient services teams with visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can:

• Expedite the benefits investigation process, allowing providers to receive a near real-time response on a patient’s coverage determination after they enter patient enrollment information;
• Provide physicians and case managers with real-time visibility into the therapy development and transportation status to coordinate patient scheduling; and
• Alert case managers of any status changes, such as delayed arrival dates, enabling them to proactively reach out to patients and caregivers to adjust scheduled treatment related events or stays, if needed.

“We are on the verge of several landmark CGT approvals this year in the United States, which reflects the rapid pace at which this sector is moving. But the healthcare system needs to keep pace with the science,” said Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen, in a press release. “We continue to focus on how we can create a more connected CGT ecosystem and introduce novel solutions that meet the needs of our biopharma partners, healthcare providers and patients.”

Reference: AmerisourceBergen Launches Cell and Gene Therapy Innovation Hub, CONSHOHOCKEN, Pa. (April 24, 2023).